KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Treasury Shares (2020 - 2026)

Supernus Pharmaceuticals has reported Treasury Shares over the past 6 years, most recently at $390496.0 for Q4 2025.

  • Quarterly Treasury Shares rose 13.29% to $390496.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $390496.0 through Dec 2025, up 13.29% year-over-year, with the annual reading at $390496.0 for FY2025, 13.29% up from the prior year.
  • Treasury Shares was $390496.0 for Q4 2025 at Supernus Pharmaceuticals, down from $393871.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $439216.0 in Q2 2025 and troughed at $20000.0 in Q4 2023.
  • The 5-year median for Treasury Shares is $260802.5 (2022), against an average of $248702.2.
  • Year-over-year, Treasury Shares plummeted 90.09% in 2023 and then surged 1623.42% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $21110.0 in 2021, then soared by 855.71% to $201750.0 in 2022, then plummeted by 90.09% to $20000.0 in 2023, then surged by 1623.42% to $344685.0 in 2024, then rose by 13.29% to $390496.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Treasury Shares are $390496.0 (Q4 2025), $393871.0 (Q3 2025), and $439216.0 (Q2 2025).